Merck Kgaa · XETR:MRK
Merck Kgaa — Q3 2025 Earnings Presentation
13 slides from Merck Kgaa's earnings presentation, November 2025
Slide 1: Q3 2025 Results: Merck Shows Solid Organic Growth Across All Sectors
Q3 2025 Results Merck Shows Solid Organic Growth Across All Sectors
Slide 2: Q3 2025: Merck shows solid organic growth across all sectors
1 Q3 2025: Merck shows solid organic growth across all sectors 2 Growth driven by strong performance in Process Solutions, Rare Diseases and Semiconductor Solutions 3 Company confirms and narrows full-year guidance for the Group
Slide 3: Disclaimer
Disclaimer Cautionary Note Regarding Forward-Looking Statements and financial indicators This communication may include “forward-looking statements.” Statements that include words such as “anticipate,” “expect,” “should,” “would,” “intend,” “plan,” “project,” “seek,” “believe,” “will,” and other wor
Slide 4: Highlights: Solid Organic Growth Across All Three Sectors
Highlights: Solid Organic Growth Across All Three Sectors Operations Group Financials Q3 YoY organic sales growth1 Life Science: Q3 organic sales: +5.2% ▪ Sustained PS growth (+10%) drives LS growth (+6%) ▪ Very strong PS order growth YoY as momentum continues Q3 organic EBITDA pre: +8.8% ▪ SLS retu
Slide 5: Financial Overview
+. ve ° ek 7 oe Po A >» %° Pt > : erhancrac. . * . a ‘overview Wa z oe eae MERCK
Slide 6: Life Science Q3: Sustaining ~10% PS Growth, SLS Returns to Growth
Life Science Q3: Sustaining ~10% PS Growth, SLS Returns to Growth Life Science P&L Net sales bridge [€m] IFRS Pre €2,210 m 5.9% 0.1% €2,241 m Q3 2024 Q3 2025 Q3 2024 Q3 2025 -4.6% Net sales 2,210 2,241 2,210 2,241 M&S -543 -545 -544 -542 +0.0% Q3 2024 Organic Currency Portfolio Q3 2025 Admin -104 -1
Slide 7: Healthcare Q3: Growing Across All Franchises, SpringWorks Contributing
Healthcare Q3: Growing Across All Franchises, SpringWorks Contributing Healthcare P&L Net sales bridge [€m] IFRS Pre €2,133 m 4.6% 4.0% €2,203 m Q3 2024 Q3 2025 Q3 2024 Q3 2025 -5.4% Net sales 2,133 2,203 2,133 2,203 M&S -416 -464 -416 -448 Q3 2024 Organic Currency Portfolio Q3 2025 Admin -73 -99 -6
Slide 8: Electronics Q3: Continuously Strong Semiconductor Materials Growth
Electronics Q3: Continuously Strong Semiconductor Materials Growth Electronics P&L Net sales bridge [€m] IFRS Pre €923 m 4.8% €875 m Q3 2024 Q3 2025 Q3 2024 Q3 2025 -4.3% -5.7% Net sales 923 875 923 875 M&S -140 -120 -141 -127 Admin -43 -14 -32 -31 Q3 2024 Organic Currency Portfolio Q3 2025 R&D -74
Slide 9: Outlook & Guidance
ouTLook & GuIDance
Slide 10: Merck Group Full-year 2025 guidance
Merck Group Full-year 2025 guidance Net sales: Organic: ~+3% YoY PF: ~+0.5% (~€60 m) FX: -5% to -3% YoY ~€20.8 – €21.4 bn EBITDA pre: Organic: +5% to +7% YoY PF: ~-0.5% (~€0m to ~€-30 m) FX: -6% to -4% YoY ~€6.0 – €6.2 bn EPS pre: ~ €8.20– €8.60 10 Merck Q3 2025 Results Presentation | November 13, 2
Slide 11: 2025 business sector guidance
2025 business sector guidance1 Net sales EBITDA pre Life Science ▪ Organic: +4% to +5% YoY ▪ Organic:+4% to +6% YoY ▪ FX: -5% to -3% YoY ▪ FX: -5% to -3% YoY ▪ ~€8.90 bn to €9.10 bn ▪ ~€2.55 bn to €2.65 bn Net sales EBITDA pre Healthcare ▪ Organic: ~+3% YoY ▪ Organic:+9% to +11% YoY ▪ PF: ~+2% (~€18
Slide 12: Q3 2025: Merck shows solid organic growth across all sectors
1 Q3 2025: Merck shows solid organic growth across all sectors 2 Growth driven by strong performance in Process Solutions, Rare Diseases and Semiconductor Solutions 3 Company confirms and narrows full-year guidance for the Group
Slide 13: PDARGREK
PDARGREK